Neuromodulation With Percutaneous Electrical Nerve Field Stimulation
NCT: NCT07492108 · ACTIVE_NOT_RECRUITING
Brief Summary
The IB-Stim is the first device to be approved by the Food and Drug Administration (FDA) for the treatment of functional abdominal pain in adolescents aged 11-18 with IBS. However, the efficacy of Percutaneous electrical nerve field stimulation (PENFS) in adults with gastroparesis like symptoms (GPLS) is not currently known. This study is a double-blind, randomized, sham-controlled pilot study evaluating the efficacy of PENFS using IB-Stim in adult patients with GPLS. A secondary aim will be to assess whether treatment with PENFS is associated with changes in autonomic function via heart rate variability.
Frequently Asked Questions
What is Neuromodulation With Percutaneous Electrical Nerve Field Stimulation?
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation is a clinical trial registered under NCT07492108. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT07492108?
The current status of NCT07492108 (Neuromodulation With Percutaneous Electrical Nerve Field Stimulation) is: ACTIVE_NOT_RECRUITING.
When did Neuromodulation With Percutaneous Electrical Nerve Field Stimulation start?
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation started on 2026-01-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.